Quince Therapeutics Has Dosed The First Patient In Phase 3 NEAT Trial To Evaluate Neurological Effects Of EryDex In Patients With Ataxia-telangiectasia, Topline Results Are Expected In 2H Of 2025 With A Potential New Drug Application Submission In 2026
Portfolio Pulse from Benzinga Newsdesk
Quince Therapeutics has initiated the Phase 3 NEAT trial to evaluate the neurological effects of EryDex in patients with Ataxia-telangiectasia. The first patient has been dosed, and topline results are expected in the second half of 2025, with a potential New Drug Application submission in 2026.
June 25, 2024 | 11:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Quince Therapeutics has dosed the first patient in its Phase 3 NEAT trial for EryDex, targeting Ataxia-telangiectasia. Topline results are anticipated in the second half of 2025, with a potential NDA submission in 2026.
The initiation of a Phase 3 trial is a significant milestone for Quince Therapeutics, indicating progress in their drug development pipeline. Positive topline results in 2025 could lead to a New Drug Application submission in 2026, potentially boosting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100